MIG Fonds et al. in €13m Antisense round
MIG Fonds and Global Asset Management have invested a further €13m in biotechnology company Antisense Pharma GmbH, with management and private investors also taking part in the financing.
MIG AG invested €11m and Global Asset Fund contributed €1.5m.
Antisense Pharma develops therapies for particularly aggressive cancers. The company’s lead product, Trabedersen, is in clinical development and selectively inhibits the production of tumour-supporting proteins. Trabedersen was awarded orphan drug status from the European and American authorities for high grade glioma (brain tumours) in 2002 and for the treatment of pancreatic cancer in 2009.
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater